Allurion Technologies shares soared 200% Friday as it planned to test its gastric balloon with the key ingredient in popular weight-loss drugs to see if the combination improves patients' muscle mass.

The Allurion intragastric balloon (IGB) is inserted through the mouth into the patient's stomach endoscopically before being expanded with 550 milliliters of water. “Over the past decade, demand for ...

according to Allurion Technologies, the Massachusetts company that makes it. Three other gastric balloons currently have ...

Allurion (ALUR) stock soared 70% after the company announced it is planning to conduct a clinical study of its gastric balloon weight-loss product in combination with GLP-1 drugs.

Another of Allurion’s key products is its gastric weight loss balloons. The company recently shared data from a study in which patients treated with Saxenda who achieved no weight loss of less ...

NATICK, Mass. - Allurion Technologies, Inc. (NYSE: ALUR), a company focused on obesity treatment solutions, has expanded its intellectual property portfolio with a newly issued U.S. patent.

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a ...

NATICK, Mass., January 23, 2025--(BUSINESS WIRE)--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity, today ...

In Malaysia, cases of overweight and obesity are now increasing at an alarming rate. Photo by Jeslyn Teh. The Allurion intragastric balloon (IGB) is inserted through the mouth into the patient's ...

Allurion Technologies announced it would begin a study to see if its gastric balloon, combined with popular GLP-1 medicines like Novo Nordisk's Wegovy, could improve muscle mass and overall body ...

NATICK, Mass. - Allurion Technologies, Inc. (NYSE: ALUR), a company focused on obesity treatment solutions, has expanded its intellectual property portfolio with a newly issued U.S. patent. According ...